Mineralys Short Long Term Debt Total vs Total Current Liabilities Analysis

MLYS Stock

12.77 0.34 2.59%

Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Short Long Term Debt Total and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Short Long Term Debt Total vs Total Current Liabilities

Short Long Term Debt Total vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Short Long Term Debt Total account and Total Current Liabilities. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Mineralys Therapeutics,'s Short Long Term Debt Total and Total Current Liabilities is -0.68. Overlapping area represents the amount of variation of Short Long Term Debt Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Short Long Term Debt Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt Total of Mineralys Therapeutics, Common are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Short Long Term Debt Total i.e., Mineralys Therapeutics,'s Short Long Term Debt Total and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.68

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Short Long Term Debt Total

Total Current Liabilities

Total Current Liabilities is an item on Mineralys Therapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mineralys Therapeutics, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 769.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 130.7 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	27K	1.7M	1.9M	2.0M
Depreciation And Amortization	18.7M	228.5K	167.9K	159.5K

Interest Expense Depreciation And Amortization

Mineralys Therapeutics, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Deferred Long Term Liab
Total Assets		-0.9	0.88	0.93	0.9	-0.88	-0.8	-0.99	0.46	0.75	0.75	0.22	-0.83	1.0	-0.78	0.99	0.97	0.24	0.89	-0.9	1.0	0.95	1.0	-0.9	0.95	0.96
Short Long Term Debt Total	-0.9		-0.64	-0.68	-0.94	0.66	0.54	0.88	-0.23	-0.45	-0.45	0.09	0.64	-0.9	0.97	-0.94	-0.94	0.08	-0.94	1.0	-0.9	-0.95	-0.9	1.0	-0.95	-0.79
Other Current Liab	0.88	-0.64		0.94	0.68	-0.95	-0.86	-0.92	0.57	0.84	0.82	0.39	-0.95	0.88	-0.47	0.83	0.79	0.46	0.66	-0.64	0.88	0.76	0.88	-0.64	0.76	0.9
Total Current Liabilities	0.93	-0.68	0.94		0.75	-0.9	-0.85	-0.93	0.51	0.84	0.85	0.39	-0.82	0.93	-0.5	0.88	0.87	0.39	0.74	-0.68	0.93	0.82	0.93	-0.68	0.82	0.94
Total Stockholder Equity	0.9	-0.94	0.68	0.75		-0.6	-0.45	-0.89	0.03	0.37	0.39	-0.23	-0.58	0.89	-0.91	0.96	0.97	-0.22	1.0	-0.94	0.9	0.99	0.9	-0.94	0.99	0.75
Net Tangible Assets	-0.88	0.66	-0.95	-0.9	-0.6		0.97	0.89	-0.77	-0.94	-0.92	-0.58	0.97	-0.89	0.47	-0.8	-0.76	-0.63	-0.58	0.66	-0.88	-0.7	-0.88	0.66	-0.7	-0.95
Net Debt	-0.8	0.54	-0.86	-0.85	-0.45	0.97		0.79	-0.89	-0.99	-0.98	-0.76	0.89	-0.8	0.34	-0.69	-0.64	-0.77	-0.43	0.54	-0.79	-0.57	-0.8	0.54	-0.57	-0.92
Retained Earnings	-0.99	0.88	-0.92	-0.93	-0.89	0.89	0.79		-0.44	-0.74	-0.73	-0.2	0.86	-0.99	0.76	-0.98	-0.97	-0.23	-0.88	0.88	-0.99	-0.95	-0.99	0.88	-0.95	-0.95
Accounts Payable	0.46	-0.23	0.57	0.51	0.03	-0.77	-0.89	-0.44		0.89	0.87	0.93	-0.7	0.47	-0.05	0.31	0.26	0.94	0.02	-0.23	0.45	0.17	0.46	-0.23	0.17	0.66
Cash	0.75	-0.45	0.84	0.84	0.37	-0.94	-0.99	-0.74	0.89		0.99	0.81	-0.85	0.75	-0.24	0.62	0.58	0.82	0.36	-0.45	0.74	0.5	0.74	-0.45	0.5	0.89
Non Current Assets Total	0.75	-0.45	0.82	0.85	0.39	-0.92	-0.98	-0.73	0.87	0.99		0.8	-0.81	0.75	-0.23	0.63	0.59	0.8	0.37	-0.45	0.74	0.5	0.75	-0.45	0.5	0.89
Non Currrent Assets Other	0.22	0.09	0.39	0.39	-0.23	-0.58	-0.76	-0.2	0.93	0.81	0.8		-0.47	0.23	0.29	0.06	0.01	0.98	-0.24	0.09	0.21	-0.1	0.22	0.09	-0.1	0.47
Other Assets	-0.83	0.64	-0.95	-0.82	-0.58	0.97	0.89	0.86	-0.7	-0.85	-0.81	-0.47		-0.83	0.49	-0.77	-0.71	-0.56	-0.56	0.64	-0.83	-0.68	-0.83	0.64	-0.68	-0.87
Cash And Short Term Investments	1.0	-0.9	0.88	0.93	0.89	-0.89	-0.8	-0.99	0.47	0.75	0.75	0.23	-0.83		-0.77	0.98	0.97	0.24	0.89	-0.9	1.0	0.95	1.0	-0.9	0.95	0.97
Common Stock Shares Outstanding	-0.78	0.97	-0.47	-0.5	-0.91	0.47	0.34	0.76	-0.05	-0.24	-0.23	0.29	0.49	-0.77		-0.85	-0.86	0.27	-0.91	0.97	-0.78	-0.89	-0.78	0.97	-0.89	-0.63
Other Current Assets	0.99	-0.94	0.83	0.88	0.96	-0.8	-0.69	-0.98	0.31	0.62	0.63	0.06	-0.77	0.98	-0.85		1.0	0.07	0.95	-0.94	0.99	0.99	0.99	-0.94	0.99	0.91
Other Stockholder Equity	0.97	-0.94	0.79	0.87	0.97	-0.76	-0.64	-0.97	0.26	0.58	0.59	0.01	-0.71	0.97	-0.86	1.0		0.02	0.97	-0.94	0.98	0.99	0.97	-0.94	0.99	0.89
Total Liab	0.24	0.08	0.46	0.39	-0.22	-0.63	-0.77	-0.23	0.94	0.82	0.8	0.98	-0.56	0.24	0.27	0.07	0.02		-0.23	0.08	0.23	-0.08	0.23	0.08	-0.08	0.47
Net Invested Capital	0.89	-0.94	0.66	0.74	1.0	-0.58	-0.43	-0.88	0.02	0.36	0.37	-0.24	-0.56	0.89	-0.91	0.95	0.97	-0.23		-0.94	0.89	0.99	0.89	-0.94	0.99	0.74
Short Long Term Debt	-0.9	1.0	-0.64	-0.68	-0.94	0.66	0.54	0.88	-0.23	-0.45	-0.45	0.09	0.64	-0.9	0.97	-0.94	-0.94	0.08	-0.94		-0.9	-0.95	-0.9	1.0	-0.95	-0.79
Total Current Assets	1.0	-0.9	0.88	0.93	0.9	-0.88	-0.79	-0.99	0.45	0.74	0.74	0.21	-0.83	1.0	-0.78	0.99	0.98	0.23	0.89	-0.9		0.95	1.0	-0.9	0.95	0.96
Capital Stock	0.95	-0.95	0.76	0.82	0.99	-0.7	-0.57	-0.95	0.17	0.5	0.5	-0.1	-0.68	0.95	-0.89	0.99	0.99	-0.08	0.99	-0.95	0.95		0.95	-0.95	1.0	0.83
Net Working Capital	1.0	-0.9	0.88	0.93	0.9	-0.88	-0.8	-0.99	0.46	0.74	0.75	0.22	-0.83	1.0	-0.78	0.99	0.97	0.23	0.89	-0.9	1.0	0.95		-0.9	0.95	0.96
Short Term Debt	-0.9	1.0	-0.64	-0.68	-0.94	0.66	0.54	0.88	-0.23	-0.45	-0.45	0.09	0.64	-0.9	0.97	-0.94	-0.94	0.08	-0.94	1.0	-0.9	-0.95	-0.9		-0.95	-0.79
Common Stock	0.95	-0.95	0.76	0.82	0.99	-0.7	-0.57	-0.95	0.17	0.5	0.5	-0.1	-0.68	0.95	-0.89	0.99	0.99	-0.08	0.99	-0.95	0.95	1.0	0.95	-0.95		0.83
Deferred Long Term Liab	0.96	-0.79	0.9	0.94	0.75	-0.95	-0.92	-0.95	0.66	0.89	0.89	0.47	-0.87	0.97	-0.63	0.91	0.89	0.47	0.74	-0.79	0.96	0.83	0.96	-0.79	0.83

Click cells to compare fundamentals

Mineralys Therapeutics, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mineralys Short Long Term Debt Total vs Total Current Liabilities Analysis

Short Long Term Debt Total vs Total Current Liabilities

Short Long Term Debt Total vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Short Long Term Debt Total

Total Current Liabilities

Mineralys Therapeutics, fundamental ratios Correlations

Mineralys Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Mineralys Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity

Net Working Capital	- 0.99	Retained Earnings
Total Current Assets	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Total Assets
Other Current Assets	- 0.98	Retained Earnings